PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation

Microvascular Research

Volumn 85, Issue 1, 2013, Pages 54-58

  Ishibashi, Yuji ^a   Matsui, Takanori ^a   Ohta, Keisuke ^b   Tanoue, Ryuichiro ^b   Takeuchi, Masayoshi ^c   Asanuma, Katsuhiko ^d   Fukami, Kei ^e   Okuda, Seiya ^e   Nakamura, Kei ichiro ^b   Yamagishi, Sho ichi ^a  

^a Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications ^*  (Japan)

^b Department of Anatomy   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE; GENE EXPRESSION REGULATION; IN VITRO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PIGMENT EPITHELIUM DERIVED FACTOR GENE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ANILIDES; ANIMALS; APOPTOSIS; CATTLE; CELL DIFFERENTIATION; ETHIDIUM; EYE PROTEINS; GENE EXPRESSION REGULATION; GLYCOPROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; MICE; NERVE GROWTH FACTORS; NEURONS; PODOCYTES; PPAR GAMMA; RNA, MESSENGER; SERPINS; SERUM ALBUMIN, BOVINE; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84871714164     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.10.007     Document Type: Article

References (42)

1. Amano S., Yamagishi S., Inagaki Y., Nakamura K., Takeuchi M., Inoue H., Imaizumi T. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc. Res. 2005, 69:45-55.
2. Chuang P.Y., Dai Y., Liu R., He H., Kretzler M., Jim B., Cohen C.D., He J.C. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011, 6:e23566.
3. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H.J., Benedict W., Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
4. Duh E.J., Yang H.S., Suzuma I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., Davarya S., Tong P., Gehlbach P., Pearlman J., Crabb J.W., Aiello L.P., Campochiaro P.A., Zack D.J. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. 2002, 43:821-829.
5. Dyer D.G., Blackledge J.A., Thorpe S.R., Baynes J.W. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J. Biol. Chem. 1991, 266:11654-11660.
6. Fujimura T., Yamagishi S., Ueda S., Fukami K., Shibata R., Matsumoto Y., Kaida Y., Hayashida A., Koike K., Matsui T., Nakamura K., Okuda S. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol. Dial. Transplant. 2009, 24:1397-1406.
7. Fukami K., Ueda S., Yamagishi S., Kato S., Inagaki Y., Takeuchi M., Motomiya Y., Bucala R., Iida S., Tamaki K., Imaizumi T., Cooper M.E., Okuda S. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 2004, 66:2137-2147.
8. Grandhee S.K., Monnier V.M. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J. Biol. Chem. 1991, 266:11649-11653.
9. Gu L., Hagiwara S., Fan Q., Tanimoto M., Kobata M., Yamashita M., Nishitani T., Gohda T., Ni Z., Qian J., Horikoshi S., Tomino Y. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 2006, 21:299-313.
10. Ide Y., Matsui T., Ishibashi Y., Takeuchi M., Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by NF-kappaB activation. Microvasc. Res. 2010, 80:227-232.
11. Lin N., Zhang H., Su Q. Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress. Diabetes Metab. 2012, 38:250-257.
12. Maeda S., Matsui T., Takeuchi M., Yoshida Y., Yamakawa R., Fukami K., Yamagishi S. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol. Res. 2011, 63:241-248.
13. Marx N., Walcher D., Ivanova N., Rautzenberg K., Jung A., Friedl R., Hombach V., de Caterina R., Basta G., Wautier M.P., Wautiers J.L. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004, 53:2662-2668.
14. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem. Biophys. Res. Commun. 2009, 24(385):269-272.
15. Matsui T., Yamagishi S., Takeuchi M., Ueda S., Fukami K., Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol. Res. 2010, 61:34-39.
16. Müller-Krebs S., Kihm L.P., Madhusudhan T., Isermann B., Reiser J., Zeier M., Schwenger V. Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol. Dial. Transplant. 2012, 10.1093/ndt/gfs005.
17. Mundel P., Heid H.W., Mundel T.M., Krüger M., Reiser J., Kriz W. Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J. Cell Biol. 1997, 139:193-204.
18. Rahbar S. Novel inhibitors of glycation and AGE formation. Cell Biochem. Biophys. 2007, 48:147-157.
19. Shankland S.J. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006, 69:2131-2147.
20. Shi S., Yu L., Sun Y., Chen J., Khitrov G., Merkenschlarger M., Holzman L.B., Zhang W., Mundel P., Bottinger E.P. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 2008, 19:2159-2169.
21. Stieger N., Worthmann K., Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab. Res. Rev. 2011, 27:207-215.
22. Stitt-Cavanagh E., MacLeod L., Kennedy C.R. The podocyte in diabetic kidney disease. Sci. World J. 2009, 9:1127-1139.
23. Tombran-Tink J., Barnstable C.J. PEDF: a multifaceted neurotrophic factor. Nat. Rev. Neurosci. 2003, 4:628-636.
24. Tombran-Tink J., Chader C.G., Johnson L.V. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 1991, 53:411-414.
25. Wang S.H., Liang C.J., Wu J.C., Huang J.J., Chien H.F., Tsai J.S., Yen Y.S., Tseng Y.C., Lue J.H., Chen Y.L. Pigment epithelium-derived factor reduces the PDGF-induced migration and proliferation of human aortic smooth muscle cells through PPARγ activation. Int. J. Biochem. Cell Biol. 2012, 44:280-289.
26. Wendt T.M., Tanji N., Guo J., Kislinger T.R., Qu W., Lu Y., Bucciarelli L.G., Rong L.L., Moser B., Markowitz G.S., Stein G., Bierhaus A., Liliensiek B., Arnold B., Nawroth P.P., Stern D.M., D'Agati V.D., Schmidt A.M. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 2003, 162:1123-1137.
27. White K.E. Research into the glomerular podocyte-is it relevant to diabetic nephropathy?. Diabet. Med. 2006, 23:715-719.
28. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
29. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
30. Yamagishi S., Inagaki Y., Okamoto T., Amano S., Koga K., Takeuchi M., Makita Z. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 2002, 77:20309-20315.
31. Yamagishi S., Inagaki Y., Amano S., Okamoto T., Takeuchi M., Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem. Biophys. Res. Commun. 2002, 296:877-882.
32. Yamagishi S., Matsui T., Inoue H. Inhibition by advanced glycation end products (AGEs) of pigment epithelium-derived factor (PEDF) gene expression in microvascular endothelial cells. Drugs Exp. Clin. Res. 2005, 31:227-232.
33. Yamagishi S., Nakamura K., Matsui T., Inagaki Y., Takenaka K., Jinnouchi Y., Yoshida Y., Matsuura T., Narama I., Motomiya Y., Takeuchi M., Inoue H., Yoshimura A., Bucala R., Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:20213-20220.
34. Yamagishi S., Matsui T., Nakamura K., Takeuchi M., Imaizumi T. Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc. Res. 2006, 72:86-90.
35. Yamagishi S., Fukami K., Ueda S., Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 2007, 8:952-959.
36. Yamagishi S., Matsui T., Nakamura K., Ueda S., Noda Y., Imaizumi T. Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr. Drug Targets 2008, 9:1025-1029.
37. Yamagishi S., Matsui T., Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr. Pharm. Des. 2009, 15:1027-1033.
38. Yamagishi S., Maeda S., Matsui T., Ueda S., Fukami K., Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim. Biophys. Acta 2012, 1820:663-671.
39. Yang S.L., Chen S.L., Wu J.Y., Ho T.C., Tsao Y.P. Pigment epithelium-derived factor induces interleukin-10 expression in human macrophages by induction of PPAR gamma. Life Sci. 2010, 87:26-35.
40. Yoshida T., Yamagishi S., Nakamura K., Matsui T., Imaizumi T., Takeuchi M., Koga H., Ueno T., Sata M. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 2006, 49:3094-3099.
41. Yoshida Y., Yamagishi S., Matsui T., Jinnouchi Y., Fukami K., Imaizumi T., Yamakawa R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev. 2009, 25:678-686.
42. Zhou L.L., Cao W., Xie C., Tian J., Zhou Z., Zhou Q., Zhu P., Li A., Liu Y., Miyata T., Hou F.F., Nie J. The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int. 2012, 10.1038/ki.2012.